期刊文献+

西格列汀合成工艺改进研究 被引量:1

Improvement of method for synthesis of sitagliptin
原文传递
导出
摘要 目的对西格列汀的合成工艺进行改进。方法以2,4,5-三氟苯乙酸为原料,经亲核取代、环化、氢化、Na BH4还原反应,并进行拆分优化。结果制得的西格列汀光学纯度高于98%、总收率36%。结论拆分方法具有操作简便、生产成本低、反应条件温和的优点,适用于西格列汀的工业化应用。 Objective To study the improved method for synthesis of sitagliptin. Methods 2,4,5-Trifluoro phenyl acetic acid was used as raw material to synthesize the target compound by nucleophilic substitution, cyclization, hydrogenation, and Na BH4 reduction. And isomer resolution was optimized. Results After optimization, sitagliptin with optical purity of 99.7% was obtained. The total recovery of the synthetic route was 36%. Conclusion The resolution method with advantages of easy-operation, low production cost, and mild reaction conditions is suitable for industrial application of sitagliptin.
出处 《现代药物与临床》 CAS 2016年第10期1513-1516,共4页 Drugs & Clinic
关键词 西格列汀 2 4 5-三氟苯乙酸 拆分优化 合成工艺 sitagliptin 2 4 5-trifluoro phenyl acetic acid resolution optimization synthetic process
  • 相关文献

参考文献10

  • 1Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action [J]. Minerva Endocrinol, 2006, 31(2): 133 -147.
  • 2许菁,王玉丽,徐为人,张士俊.治疗2型糖尿病的新型药物——西他列汀[J].中国药物与临床,2007,7(11):861-863. 被引量:8
  • 3Hansen K B, Hsiao Y, Xu F, et al. Highly efficient asymmetric synthesis of sitagliptin [J]. J Am Chem Soc, 2009, 131(25): 8798-8804.
  • 4Kim D, Wang L P, Beconi M, et al. (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for thetreatment of type 2 diabetes [J]. J Med Chem, 2005, 48(1): 141-151.
  • 5Hansen K B, Balsells J, Dreher S, et al. First generation process for the preparation of the DPP-IV inhibitor Sitagliptin [J]. Org Pro Res Dev, 2005, 9(5): 634-639.
  • 6陈清奇.新药化学全合成路线手册(1999-2007)[M].北京:科学出版社,2008,366-370.
  • 7Bazin H G Bess L S, Livesay M T, et al. New synthesis of glycolipid immunostimulants RC-529 and CRX-524 [J]. Tetrahedron Lett, 2006, 47(13): 2087-2092.
  • 8Dreher S D, Ikemoto N, Njolito E, et al. Process to chiral beta-amino acid derivatives [P]. WO: 2004085661, 2004-10-07.
  • 9Xiao Y, Armstrong J D, Krska S W, et al. Process for the preparation of chiral beta-amino acid derivatives by asymmetric hydrogenation [P]. WO: 2004085378, 2004-10-07.
  • 10Wenslow R M, Armstrong J D, Chen A M, et al. Novel crystal forms of a dihydrogen phosphate salt of a tfizolopyrazine dipetidyl prtidase IV inhibitor [P]. WO: 2005020920, 2005 -03 - 10.

二级参考文献15

  • 1Gallwitz B.Therapies for the treatment of type 2 diabetes mellitus based on incretinaction.Minerva Endocrinol,2006,31(2):133-147.
  • 2Ahren B,Landin-olsson M,Jansson PA,et al.Inhibition of dipeptidyl peptidase-4 reduces glycemia,sustains insulin levels,and reduces glucagon levels in type 2 diabetes.J Clin Endocrinol Metab,2004,89(5):2078-2084.
  • 3Mu J,Woods J,Zhou YP,et al.Chronic Inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes.Diabetes,2006,55(6):1695-1704.
  • 4Drucker DJ,Nauck MA.The incretin system:glucagons-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet,2006,368(9548):1696-1705.
  • 5Aschner P,Kipnes MS,Lunceford JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.Diabetes care,2006,29(12):2632-2637.
  • 6Kim D,Wang L,Beconi M,et al.(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:a potent,orally active dipeptidyl peptidase-Ⅳ inhibitor for the treatment of type 2 diabetes.J Med Chem,2005,48(1):141-151.
  • 7Herman GA,Berqman A,Stevens C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.Clin Endocrinol Metab,2006,91(11):4612-4619.
  • 8Miller S,Stonge EL.Sitagliptin:a dipeptidyl peptidase Ⅳ Inhibitor for the treatment of type 2 diabetes.Ann Pharm,2006,40(7-8):1336-1343.
  • 9Scott R,Wu M,Sanchez M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.Int J Clin Pract,2007,61(1):171-180.
  • 10Charbonnel B,Karasik A,Liu J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Care,2006,29 (12):2638-2643.

共引文献7

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部